In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ascenta Therapeutics Inc.

www.ascenta.com

Latest From Ascenta Therapeutics Inc.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Deals M & A

Ascletis Eyes Launch Of China’s First Oral HCV Drug, Possible IPO

Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.

Commercial Companies

Deals Shaping the Medical Industry (10/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Debiopharm and Ascenta in a deal to develop early-stage anticancer compound

The Swiss Debiopharm Group and US-based Ascenta Therapeutics have entered into an exclusive worldwide license development and commercialisation agreement for the Phase I compound, AT-406 (also, Debio 1143) for the treatment of various cancers.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ascenta Therapeutics Inc.
  • Senior Management
  • Joel F Sussman, CFO
    Lance Leopold, MD, VP, Clin. Dev. & CMO
  • Contact Info
  • Ascenta Therapeutics Inc.
    Phone: (610) 408-0301
    101 Lindenwood Dr.
    Ste. 405
    Malvern, PA 19355
    USA
UsernamePublicRestriction

Register